The generic alternative in schizophrenia: opportunity or threat?

CNS Drugs
Philippe NussMartina Hummer

Abstract

Pharmacological treatment of schizophrenia often requires careful dosage titration to achieve satisfactory symptom control whilst minimising the risk of adverse effects. Relapses requiring hospitalisation are an important potential source of additional cost for the health service and any inadequate symptom control increases the indirect costs of schizophrenia relating to, for example, the need for sheltered accommodation or intensive social services support. The availability of generic drugs is widely regarded as an opportunity to reduce expenditure on drug costs and deploy limited resources more widely and effectively. However, generic drugs may differ from branded drugs in their formulation and may not show precise bioequivalence with the branded product. This may have consequences for the pharmacokinetic profile of the generic drug. A higher maximum plasma concentration (C(max)) could lead to increased or emergent adverse effects, whereas a decreased absorption or minimum plasma concentration (C(min)) may result in a reduced therapeutic effect. For example, plasma levels of clozapine are critical to therapeutic response. Symptom aggravation occurred in approximately 10% of patients switched from branded to generic clozapine ...Continue Reading

References

Oct 1, 1996·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·P A Meredith
Jul 28, 1999·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·E M Vasquez, D I Min
Oct 18, 2000·Statistics in Medicine·M L ChenR Williams
Nov 7, 2000·PharmacoEconomics·E Lindström, K Bingefors
Jan 12, 2001·European Archives of Psychiatry and Clinical Neuroscience·A Jablensky
Jun 12, 2002·CNS Drugs·Jonathan S E Hellewell
Jan 8, 2003·PharmacoEconomics·Silvia M EssThomas D Szucs
Mar 18, 2003·The Annals of Pharmacotherapy·Eugene H MakelaErdogan Gunel
Mar 29, 2003·Psychiatric Services : a Journal of the American Psychiatric Association·Patricia ThiedaJohn Kane
Dec 24, 2003·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Hisashi IijimaMakoto Shiragami
Dec 25, 2003·Clinical Therapeutics·Peter Meredith

❮ Previous
Next ❯

Citations

Apr 27, 2013·CNS Drugs·Maren Carbon, Christoph U Correll
Dec 1, 2008·Expert Review of Pharmacoeconomics & Outcomes Research·Steven Simoens
Dec 1, 2008·Expert Review of Pharmacoeconomics & Outcomes Research·A Aleksander AraszkiewiczAlan Haycox
Mar 17, 2015·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Zoltán KalóDiana Brixner
Apr 11, 2015·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Ewa Bałkowiec-IskraDagmara Mirowska-Guzel
Oct 2, 2012·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Johannes HamannStefan Leucht
Jan 2, 2010·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·William V BoboRichard C Shelton

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here